Interleukin-1 Receptor Antagonists and Other Markers in Colorectal Cancer Patients

References

• Fong Y, Moldawer L L, Shires G T, Lowry S F. The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 1990; 170: 363–78
   PubMedGoogle Scholar
• Waage A, Espevik T, Halstensen A. TNF, IL-1 and IL-6 in human septic shock. Scand J Immunol 1988; 28: 267–71
   Google Scholar
• Girardin E, Grau G E, Dayer J M, Roux-Lombard P, Lambert P H. Tumour necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319–400
   Google Scholar
• Sullivan J S, Kilpatrick L, Costarino A T, Lee S C, Harris M C. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992; 120: 510–5
   PubMed Web of Science ®Google Scholar
• Okisawa S, Gelfand J A, Ikejima T, Connolly R J, Dinarello C A. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumour necrosis factor and the effect of cyclooxygcnase inhibition. J Clin Invest 1988; 81: 1162–72
   PubMedGoogle Scholar
• Waage A, Espevik T. Interleukin-1 potentiates the lethal effect of tumour necrosis factor/cachectin in mice. J Exp Med 1988; 167: 1987–92
   PubMed Web of Science ®Google Scholar
• Dayer J M. Chronic inflammatory joint disease: natural inhibitors of interleukin-1 and tumour necrosis factor-?. J Rheumatol 1991; 18: 71–5
   Google Scholar
• Larrick J W. Native interleukin-1 inhibitors. Immunol Todav 1989; 10: 61–6
   PubMedGoogle Scholar
• Dinarello C A. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–52
   PubMed Web of Science ®Google Scholar
• Eisenberg S P, Brewer M T, Verderber E, Heimdal P, Brandhuber B J, Thompson R C. Interleukin-1. receptor antagonist is a member of the interleukin-l gene family xvolution of a cytokine control mechanism. Proc Natl Acad Sci USA 1991; 88: 5232–6
   PubMed Web of Science ®Google Scholar
• Granowitz E V, Clark B D, Mancilla J, Dinarello C A. Interieukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the tvpe II interleukin-1 receptor. J Biol Chem 1991; 266: 14147–50
   PubMed Web of Science ®Google Scholar
• Dripps D J, Brandhuber B J, Thompson R C, Eisenberg S P. Effect of IL-lra on IL-1 signal transduction. J Biol Chem 1991; 266: 10331–6
   PubMed Web of Science ®Google Scholar
• Henderson B, Thompson R C, Hardingham T, Lewthwaite J. Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 1991; 3: 246–9
   PubMed Web of Science ®Google Scholar
• Alexander H R, Doherty G M, Venzon D J, Merino M J, Fraker D L, Norton J A. Recombinant interleukin-1 receptor antagonist (IL-lra): effective therapy against gram-negative sepsis in rats. Surgery 1992; 112: 188–94
   PubMedGoogle Scholar
• Cominelli F, Nast C C, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103: 5–71
   Google Scholar
• Di Padova F, Pozzi C, Tondre M J, Tritpepe R. Selective and early increase of IL-1 inhibitors, IL-6 and Cortisol after elective surgery. Clin Exp Immunol 1991; 85: 137–42
   PubMed Web of Science ®Google Scholar
• Penn I. Why do immunosuppressed patients develop cancer?. Crit Rev Oncog 1989; 1: 27–52
   PubMedGoogle Scholar
• Anaissie E J, Bodey G P. Fungal infection in patients with cancer. Pharmacotherapy 1990; 10: 164–9
   Google Scholar
• Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 1992; 70: 709–13
   PubMed Web of Science ®Google Scholar
• Danis V A, Kulesz A J, Nelson D S, Brooks P M. Cytokine regulation of human monocyte interleukin-1 production in vitro. Enhancement of IL-1 production by interferon-gamma, tumour necrosis factor-aloha and IL-2 and IL-1, and inhibitory by interferon-alpha. Clin Exp Immunol 1990; 80: 435–43
   PubMedGoogle Scholar
• Segal G M, McCall E, Bagby G C. Erythroid burst-promoting activity produced by interleukin-1 stimulated endothelial cell is granulocyte-macrophage colony-stimulating factor. Blood 1988; 72: 1364–7
   PubMed Web of Science ®Google Scholar
• Broudy V C, Kaushansky K, Harlan J M, Adamson J W. Interleukin-1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J Immunol 1987; 139: 464–8
   PubMed Web of Science ®Google Scholar
• Kaushansky N, Lin N, Adamson J V. Interleukin-1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony-stimulating factor. J Clin Invest 1988; 81: 92–7
   PubMed Web of Science ®Google Scholar
• Auron P E, Webb A C, Rosenwasser L J, Mucci S F, Rich A, Wolff S M. Nucleotide sequency of human monocyte interleukin-1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81: 7907–11
   PubMed Web of Science ®Google Scholar
• Conti P, Panara M R, Porrini A M. Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor by a novel cytokine intcrleukin-1 receptor antagonist. Scand J Immunol 1992; 36: 27–33
   PubMedGoogle Scholar
• Nicold L P, El Habre F, Dayer J M. Natural and recombinant interleukin 1 receptor antagonist does not inhibit human T-cell proliferation induced by mitogens, soluble antigens or allogeneic determinations. Cytokine 1992; 4: 29–35
   PubMedGoogle Scholar
• Faherty D A, Claudy V, Plocinski J M. Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo. J Immunol 1992; 148: 766–71
   PubMedGoogle Scholar
• Granowitz E V, Porat R, Mier J W. Pharmacokinetics, safety and immunomodulatory effects of humanrecombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4: 353–60
   PubMed Web of Science ®Google Scholar
• Svenson M, Nedergaard S, Heegaard P M, Whisenand T D, Arend W P, Bendtzen K. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors. Eur J Immunol 1995; 25: 2842–50
   PubMed Web of Science ®Google Scholar
• Robb R J, Munck A, Smith K A. T cell growth factors: quantitation specificity and biologic relevance. J Exp Med 1981; 2: 319–33
   Google Scholar
• Robb R J. Interleukin-2; the molecule and its function. Immunol Today 1984; 5: 203–9
   PubMedGoogle Scholar
• Cantrell D A, Smith K A. Transient expression of interleukin-2 receptors: consequences for T cell growth. J Exp Med 1983; 158: 1895–911
   PubMed Web of Science ®Google Scholar
• Nelson D L, Rubin R A, Kurman C C, Fritz M E, Boutin B. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol 1986; 6: 114–20
   PubMed Web of Science ®Google Scholar
• Harrington D S, Patil K, Lai P K. Soluble interleukin-2 receptors in patients with malignant lymphoma. Arch Pathol Lab Med 1988; 112: 597–601
   PubMed Web of Science ®Google Scholar
• Semenzato G, Bambara L, Biasi D. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rhematoid arhtritis. J Clin Immunol 1988; 8: 447–51
   PubMedGoogle Scholar
• Lai K N, Leung J, Lai F M, Tarn J S. Early T lymphocyte activation in IgA nephropathy: soluble interleukin-2 receptor (IL-2r) production, cellular IL-2r expression and interleukin-2 release. J Clin Immunol 1989; 9: 485–92
   PubMedGoogle Scholar
• Lai K N, Stephen H, Leung J, Tsao S Y. Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. Cancer 1991; 67: 2180–5
   PubMedGoogle Scholar
• Poulakis N, Sarandakou A, Rizos D, Phocas I, Kontozoglou T H, Polyzogopoulos D. Soluble interleukin-2 receptors and other markers in primary lung cancer. Cancer 1991; 68: 1045–9
   PubMed Web of Science ®Google Scholar
• Grimm E A, Mazumder A, Zhang H Z, Rosenberg S A. Lympho-kine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–47
   PubMed Web of Science ®Google Scholar
• Fischer E, van Zee K J, Marano M A. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992; 79: 2196–200
   PubMed Web of Science ®Google Scholar
• Dinarello C A. Role of interleukin-1 in infectious disease. Immunol Rev 1992; 127: 119–46
   PubMedGoogle Scholar